Biosensis offers new Oligomeric Amyloid-Beta ELISA kit. The FDA have recently released "Biomarker Letter of Support" 
Biosensis banner
FDA endorses biomarkers for Alz and PD

Dear Doctor    
The FDA have recently released "Biomarker Letter of Support" to "encourage further study and use of CSF analytes Aβ1-42, total Tau, and phosphotau, as exploratory prognostic biomarkers for enrichment in trials for Alzheimer's Disease (AD)". This Letter also states "No specific CSF biomarker test system or assay validation process is endorsed by FDA". The full contents of the Letter can be seen here.

 

Biomarkers are urgently needed to assist clinical trials for the treatment of Alzheimer's Disease and the Biosensis ELISA kits are aimed at assisting researchers to get the highest quality products to assist with Biomarker research.  

  

Talk to Biosensis for CE-Marked ELISA kits for any clinical Biomarker studies.

Biosensis Oligomeric Aβ (oAβ) ELISA Kit 
Biosensis' Oligomeric Amyloid beta (oAβ) ELISA Kit (BEK-2215-2P) is built upon the anti-amyloid beta monoclonal MOAB-2 (M-1586-100). This is the first oligomeric amyloid beta ELISA to take advantage of MOAB-2's high specificity and avidity for beta amyloid peptides and combine it in a proprietary formulation that allows for the detection of amyloid beta oligomers and complexes present in mouse and human CSF and brain tissue extracts.

  • This is the first of a family of critical Alzheimer's Disease biomarker assays to be released by Biosensis for neurological disease research.
  • Biosensis retains exclusive worldwide rights for MOAB-2 based immnoassays. 

 

Biosensis' oAβ ELISA has recently been published in the below papers:

 

Combes M, et al. (2014) "Glutamate protects neuromuscular junctions from deleterious effects of β-amyloid peptide and conversely: An in vitro study in a nerve-muscle coculture." J Neurosci Res. 93(4):633-43, PMID:  25491262. Species: Rat neurites & human muscle cell co-culture supernatants. 

 
Liu Y, et al. (2014) "IKKbeta Deficiency in Myeloid Cells Ameliorates Alzheimer's Disease-Related Symptoms and Pathology." J Neurosci. 34(39):12982-99, PMID: 25253847.  Species: Transgenic Mouse brain lysates.

 

Tai LM, et al. (2014) "Amyloid-β Pathology and APOE Genotype Modulate Retinoid X Receptor Agonist Activity in vivo." J Biol Chem. 289(44):30538-55, PMID: 25217640. Species: EFAD-Tg mice.

 

Seo Dong Han, et al. (2015) "Plasma-enabled sustainable elemental lifecycles: honeycomb-derived graphenes for next-generation biosensors and supercapacitors." Green Chem. 17, 2164-2171. Species: Synthetic constructs.

 

Biosensis' MOAB-2 monoclonal antibody has recently been published in the below papers:

 

Iulita MF, et al. (2014) "Intracellular Aβ pathology and early cognitive impairments in a transgenic rat model overexpressing human amyloid precursor protein: a multidimensional study." Acta Neuropathol Commun. 2:61, PMID: 24903713. Application: IF, IH

Smith BR, et al. (2014) "Neuronal inclusions of alpha-synuclein contribute to the pathogenesis of Krabbe disease." J Pathol. 232(5):509-21, PMID: 24415155. Application: IF

 

Condello C, et al. (2015) "Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques." Nat Commun. 6:6176, PMID: 25630253. Application: IF

Use it for transgenic animal and disease tissue research:

BEK-2215-2P Graph 1

 

Figure: Soluble Aβ42 and soluble oligomeric Aβ levels are higher in E4FAD mice compared with E2FAD and E3FAD mice. ApoE, Aβ42, and oAβ in the TBS/soluble extraction fraction of the (A) cortex and (B) hippocampus in 6-month EFAD mice measured by ELISA. Data are expressed as mean ± SEM and were analyzed by one-way ANOVA followed by Tukey's multiple comparison post-hoc analysis. #p < 0.05 vs. apoE2 and apoE3.
 



 

     

 

Use it for human CSF research:   BEK-2215-2P Graph 2  

Figure: Oligomeric Aβ, Aβ42 in human CSF. (A) Standard curve for oligomeric Aβ ELISA: 0-500 ng/ml of oligomeric-, fibrillar- and unaggregated-Aβ42 preparations. (B) oAβ measured in the CSF from age matched control subjects (APOE3/3) and AD patients (APOE3/3 and APOE4/4)... Data are expressed as mean ± SEM, analyzed by one-way ANOVA followed by Tukey's multiple comparison post-hoc analysis.  p < 0.05. L.O.D = Limit of detection.  

 

Tai LM, et al. (2013) The Journal of Biological Chemistry. 288(8): 5914-26, PubMed ID: 23293020.   

 

Coming soon: MOAB-2 based Aβ/APOE & Aβ/APOJ complex ELISAs ONLY from Biosensis.
 By researchers for researchers!

The staff at Biosensis have many years of combined experience in manufacturing and working with antibodies and have published over 340 peer reviewed research publications in the field of neuroscience. We guarantee to provide you with the antibody information you need to get your research published

 

If you have a query on any of our products, one of our experienced researchers can help at biospeak@biosensis.com.

 

Until then, good luck with your research.
Sincerely,
The Biosensis Team
Quick Links
Contact Information
Biosensis Pty Ltd
Address: 40-46 West Thebarton Road
Thebarton SA 5031 Australia
Email: info@biosensis.com
Phone: + 61 8 8352 7711 - In the United States, call us in California toll free on 1800 605-5127
Web: www.biosensis.com